Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C752 CAR-T in CD19+ R/R B-cell NHL
NCT06210243Phase 1Terminated
- Start
- Dec 2023
- Primary completion
- Dec 2024
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of C-752 in B-cell non-Hodgkin lymphoma. Primary endpoints: Incidence and severity of adverse events at 1 year and Dose Limiting Toxicities at 28 days. Started Dec 2023; status: terminated.
02
Drugs
C-752
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT06210243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06210243.